Veralto Corporation (VLTO) | The Buildout — AI Infrastructure

The Verdict

Veralto is a group of operating companies that make the equipment and chemistry used to monitor, treat and protect water, and to keep packaged goods authentic and compliant. Its Water Quality segment sells water analytics, UV and membrane disinfection systems and treatment chemicals; its Product Quality & Innovation segment sells marking and coding, packaging-design software, traceability and color-management tools. In the AI buildout, its role is indirect: data-center cooling and process-water needs pull demand for water treatment chemicals and analytics, and AI also sits inside its compliance software as a feature rather than the reason customers buy.

Earnings Beat

Q2 2026 total sales grew 7.6% year-over-year to $1,474 million, with core sales growth of 4.2%. Gross margin was 61.2%, up from 60.0% a year earlier. Standouts: free cash flow of $328 million, adjusted EPS up 19.4%, and both segments accelerating sequentially from Q1. Q2 margin included a nonrecurring $16 million IEEPA tariff refund worth 110 basis points.

Management tone: Management's language tightened across the two 2026 calls. Earlier framing used the words steady and balanced; the Q2 2026 call added step change in 2027 and 2028, firing on all cylinders, and a flywheel of innovation that is accelerating. Management was candid that Q2 margin expansion was substantially a nonrecurring tariff refund, and it drew a clear line between one-time items and operating performance.

Management Guidance

Management guided FY26 adjusted EPS to $4.35–$4.43, a second raise representing 12%–14% growth year-over-year. Second-half 2026 core sales growth is guided to approximately 5%–6%, led by volume with pricing moderating slightly but still at or slightly above the high end of the 100–200 bps range. Full-year margin expansion is guided to 25–50 bps, with roughly 25 bps in Q3 and more than 50 bps in Q4, largely led by PQI. The cost program is expected to add a few million dollars in Q4 2026, about 50% of run-rate savings in 2027 and full run-rate in 2028. No further IEEPA refunds are included in the second-half guide.

Trajectory

Revenue has held in a narrow band across the last four quarters — $1,404M, $1,396M, $1,422M and $1,474M — with the latest print up 3.7% sequentially. Core sales growth accelerated from 1.9% in Q1 2026 to 4.2% in Q2, and management guides it to roughly 5%–6% in the second half. Gross margin expanded 110 basis points, but operating and EBITDA margins compressed, and Q2's adjusted operating margin leaned on a nonrecurring $16 million tariff refund worth 110 basis points. Trailing free cash flow conversion was 106% of net income.

The Model

The model projects FY+1 revenue of $5,935M and EBITDA of $1,496M (25.2% margin), then FY+2 revenue of $6,380M and EBITDA of $1,678M (26.3%). The near-term anchor is management's guided second-half core growth of roughly 5%–6% plus a small fourth-quarter cost-program lift; FY+2 assumes the cost program reaches full run-rate in 2028 and the M&A flywheel keeps adding recurring-revenue assets.

Projections are the median of 5 independent model runs. The model’s revenue sits 1.8% above analyst consensus.

Management guided FY26 adjusted EPS to $4.35–$4.43, a second raise representing 12%–14% growth year-over-year. Second-half 2026 core sales growth is guided to approximately 5%–6%, led by volume with pricing moderating slightly but still at or slightly above the high end of the 100–200 bps range. Full-year margin expansion is guided to 25–50 bps, with roughly 25 bps in Q3 and more than 50 bps in Q4, largely led by PQI. The cost program is expected to add a few million dollars in Q4 2026, about 50% of run-rate savings in 2027 and full run-rate in 2028. No further IEEPA refunds are included in the second-half guide.

What Could Go Right — and Wrong

Looking Ahead

Over the next 12 months, the key tests are the guided second-half core acceleration to roughly 5%–6%, the PQI-led fourth-quarter margin uplift, and the first small cost-program contribution in Q4 2026. The Cleanwater1 acquisition, signed for $465 million, is pending with a close date not disclosed. Management also points to Trojan UV bookings that ship largely in Q4 2027 and to continued M&A from an active funnel.

Financials

Annual Summary

Key Ratios (Trailing)

The Company

Veralto is a group of operating companies whose stated purpose is 'Safeguarding the World's Most Vital Resources.' Its Water Quality segment sells water analytics, UV and membrane disinfection systems, and treatment chemicals used by public and private utilities and industrial customers, from source water to the consumer and back into the water cycle. Its Product Quality & Innovation segment sells marking and coding, packaging-design software, ingredient traceability and color management used by brand owners in consumer goods, food and beverage, pharmaceutical and industrial markets.

Veralto operates a decentralized model of individual operating companies under the Veralto Enterprise System, a continuous-improvement framework. It runs 60 facilities — 21 in the United States across 12 states and 39 outside, primarily in Europe — with about 17,000 associates. About 60% of revenue is recurring, and roughly 50% of water revenue comes from industrial applications, most of that in North America. The company describes a value-creation algorithm of mid-single-digit core sales growth with 30% to 35% fall-through, with a stated first bias toward M&A.

Business Segments

Competitive Landscape

Veralto describes its preference for sticky, razor-and-razorblade businesses where it sits inside the customer's operating environment; about 60% of revenue is recurring. In filings, Dover is a documented competitor in marking and coding through its Imaging & Identification segment, which competes with Veralto's Videojet. The supply-chain wiring also lists Xylem, Ecolab, Solenis and Mettler-Toledo as inferred competitors, but those are not company-named.

Supply Chain

Veralto sits upstream of water utilities and industrial water users, selling analytics, treatment chemicals and disinfection equipment. Its component suppliers are mostly inferred, and the 10-K flags sole-source supplier risk without naming any counterparty.